Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept

Trial Profile

A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics; Registrational
  • Sponsors Corium International
  • Most Recent Events

    • 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
    • 16 Mar 2022 According to a KemPharm media release, ADLARITY has been approved (donepezil transdermal system) by the U.S. Food and Drug Administration (FDA) on March 11, 2022. ADLARITY is an innovative new treatment option for patients with mild, moderate, or severe dementia of the Alzheimer's type.
    • 16 Mar 2022 According to a KemPharm media release, the Company has earned a $1.975 million fee from Corium, Inc., (Corium), a portfolio company of Gurnet Point Capital, following the approval of Corium product ADLARITY by the U.S. Food and Drug Administration (FDA).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top